Latest news with #CitadelAdvisors
Yahoo
3 days ago
- Business
- Yahoo
Here Are Billionaire Ken Griffin's 5 Biggest Stock Holdings
Key Points Citadel's incredibly successful hedge fund performance has helped make CEO Ken Griffin a billionaire. Investors can get a look at Citadel's moves each quarter with the company's 13F filing. Citadel held more than 14,300 stock positions as of its last update, but a handful of stocks account for a relatively large share of the portfolio. These 10 stocks could mint the next wave of millionaires › Ken Griffin has the distinction of being one of history's most successful investors. The billionaire founded and leads Citadel Advisors -- the most profitable hedge fund of all time. While not all of Griffin and Citadel's trades are immediately made public, disclosure requirements from the Securities and Exchange Commission (SEC) mean that the hedge fund's holdings are disclosed quarterly through 13F filings. Read on for a look at Citadel's five largest stock holdings. The top five Citadel's technology- and analytics-focused approach to portfolio construction and history of market-crushing performance make the hedge fund's holdings a point of interest for many investors. These are the fund's five biggest stock positions as of the company's most recent public disclosure: Charles Schwab (NYSE: SCHW) is a longtime leader in financial services and stands as Citadel's top stock holding. The stock accounted for roughly 1.6% of Citadel's total stock portfolio as of the company's last update. Invesco QQQ Trust (NASDAQ: QQQ) is an exchange traded fund (ETF) that tracks the Nasdaq-100 index and accounted for 1.1% of Citadel's holdings as of the most recent public update. Edwards Lifesciences (NYSE: EW) is a medical technology specialist focused on services for patients with heart-valve disease and accounted for 1% of Citadel's stock portfolio weight. Medtronic (NYSE: MDT) is a medical company that makes devices used to treat and manage a wide range of health issues, and its stock recently represented roughly 0.8% of Citadel's portfolio holdings. Keurig Dr Pepper (NASDAQ: KDP) is a beverage giant that produces and markets a portfolio of globally known drinks. It recently made up roughly 0.7% of Citadel's stock holdings. Notably, Hess had been Citadel's second-largest position and accounted for roughly 1.3% of the fund's stock holdings as of the company's last 13F filing, but the energy company was acquired by Chevron in July in a $55 billion all-stock deal. If Griffin and Citadel opt to hold on to the Chevron stock received through the buyout, the fund could show a new top-five holding with its next 13F filing. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $473,820!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $43,540!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $653,427!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 11, 2025 Charles Schwab is an advertising partner of Motley Fool Money. Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chevron and Edwards Lifesciences. The Motley Fool recommends Charles Schwab and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic, short January 2026 $85 calls on Medtronic, and short September 2025 $92.50 calls on Charles Schwab. The Motley Fool has a disclosure policy. Here Are Billionaire Ken Griffin's 5 Biggest Stock Holdings was originally published by The Motley Fool
Yahoo
18-07-2025
- Business
- Yahoo
Hedge Funds Win Big on Chevron's $53B Hess Deal
After nearly two years of legal limbo and uncertainty, Chevron (NYSE:CVX) has officially sealed its $53 billion acquisition of Hess merger arbitrageurs are walking away with a big win. Top hedge funds like Citadel Advisors, Adage Capital Management, and HBK Investments had collectively piled nearly $10 billion into Hess shares by March, betting the deal would eventually go through. That bet just paid off. The closure came after an arbitration panel ruled in Chevron's favor, ending Exxon Mobil's challenge over Guyana oil rights that had cast a shadow over the transaction since late 2022. The uncertainty wasn't just legalit was also psychological. The deal's spread widened to over $20 at one point, reflecting how murky the odds had become. Yet firms like Westchester Capital stuck with it. The Hess stake was the largest position we've had in 15 years, said co-CIO Roy Behren, who noted the firm held about $350 million worth of Hess shares. Adage, for its part, was sitting on 10 million sharesworth north of $1.5 billion. Citadel and HBK each had over $1 billion in exposure too. The key? Betting not just on legal outcomes, but on how energy companies have historically handled joint venture agreements. The Hess-Chevron deal isn't happening in a vacuum. It's part of a broader rebound in merger arb strategies. Just this month, Synopsys closed its $35 billion buyout of Ansys after securing China's approval, another high-stakes transaction that had traders holding their breath. With billions in capital now freed up from these resolved positions, funds are scanning the horizon for the next complex, headline-grabbing tie-up. The pipeline is formingand after a long dry spell, the appetite for risk is coming back. This article first appeared on GuruFocus. Sign in to access your portfolio
Bloomberg
18-07-2025
- Business
- Bloomberg
Hedge Funds Reap Windfall as $10 Billion Hess Deal Bet Pays Off
Hedge fund managers including Citadel Advisors, Adage Capital Management and HBK Investments are reaping a windfall as the year's largest pending corporate tie-up — Chevron Corp.'s $53 billion takeover of Hess Corp. — finally crosses the finish line. Firms that specialize in merger arbitrage — essentially betting on a deal's outcome — have long wagered that the acquisition would go through, despite a challenge from Exxon Mobil Corp. that threw the transaction into limbo for 20 months. The deal's closure on Friday following a ruling by an arbitration court marks a huge victory to those who had stuck to their bets.
Yahoo
09-06-2025
- Business
- Yahoo
Do Billionaires Ken Griffin and Izzy Englander Know Something About Palantir That Wall Street Doesn't?
Griffin's and Englander's hedge funds bought Palantir shares hand over fist in Q1. However, many Wall Street analysts aren't so bullish about the stock -- mainly because of valuation concerns. The two billionaires' options strategies might align them more closely with the consensus Wall Street take on Palantir than meets the eye. 10 stocks we like better than Palantir Technologies › Only one S&P 500 stock has outperformed Palantir Technologies (NASDAQ: PLTR) so far this year. But it's a pretty close contest. NRG Energy's shares have soared around 76% year to date, while Palantir's gain lags by only a few percentage points. Despite Palantir's tremendous momentum, many analysts aren't upbeat about the stock's near-term prospects. But do billionaires Ken Griffin and Izzy Englander know something about Palantir that Wall Street doesn't? At the end of 2024, Griffin's Citadel Advisors owned 441,755 shares of Palantir. In the first quarter of 2025, the hedge fund more than tripled its position in the artificial intelligence (AI) software provider. Englander is arguably even more enthusiastic about Palantir. In the first quarter, his Millennium Management hedge fund more than quadrupled its stake to 1,312,758 shares. Both successful investors also employed options strategies with the stock. Griffin's and Englander's hedge funds held both call and put options for Palantir at the end of the first quarter. While these two billionaires are indisputably buying Palantir Technologies shares hand over fist, the stock doesn't make up a large percentage of their portfolios. That's not surprising, though, considering that Griffin's Citadel Advisors has more than 5,800 holdings, while Englander's Millennium Management has more than 3,900 holdings. Wall Street doesn't seem to share Griffin's and Englander's optimism about Palantir. The consensus 12-month price target for the stock among analysts surveyed by LSEG is roughly 22% below the current share price. Only one of the 25 analysts polled by LSEG in June rated Palantir as a "strong buy." Another three analysts recommended buying the stock. However, seven analysts viewed Palantir as an "underperform" or advised investors to sell. Fifteen analysts recommended holding the stock. Why isn't Wall Street as enthusiastic about Palantir as the two billionaire hedge fund managers seem to be? Probably the biggest objection for analysts is valuation. Palantir's shares trade at nearly 244 times forward earnings. I'd say that was a nosebleed forward multiple, but that might not be a strong enough description. Most analysts don't seem to think Palantir's growth prospects justify this sky-high valuation, either. The software company's price-to-earnings-to-growth (PEG) ratio based on analysts' five-year earnings growth projections is 4.22. PEG ratios generally need to be below 1.0 for a stock to be considered attractively valued. Maybe Griffin and Englander do know something about Palantir that most analysts on Wall Street don't. Perhaps the billionaire investors expect much stronger growth from the company than analysts forecast. Maybe they agree with Wedbush's Dan Ives, who predicts that Palantir's market cap will more than triple to $1 trillion over the next two to three years. I suspect, though, that the more bearish opinion held by Jefferies analyst Brent Thill is a better take. Thill noted on CNBC's Closing Bell Overtime show a few weeks ago that no tech stock has ever been able to sustain a super-high multiple like Palantir's. Like Thill, I don't question the strength of Palantir's underlying business. The company makes great software. It should have strong growth prospects. Palantir might even enjoy a bonanza if President Donald Trump's Golden Dome missile defense system is funded by Congress and the company wins a lucrative contract to help build it. But this growth still doesn't seem to be enough to justify Palantir's valuation, in my view. I also wonder whether Griffin and Englander are really as bullish about Palantir as their recent buying indicates. We don't know the detailed information about the option trades they've made. It's possible that those options significantly hedge their positions in Palantir. After all, hedging is what hedge funds do. Maybe, just maybe, Griffin and Englander are more closely aligned with the consensus Wall Street view of Palantir than meets the eye. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Do Billionaires Ken Griffin and Izzy Englander Know Something About Palantir That Wall Street Doesn't? was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
05-06-2025
- Business
- Yahoo
Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks
Investors have been hit with a great deal of volatility and uncertainty in the markets lately. Even so, these two companies are healthcare leaders that can still perform well. Both have solid growth prospects and have increased their payouts for a combined 101 years. 10 stocks we like better than Medtronic › Some stock-trading platforms enable their users to automatically replicate the positions taken by experienced investors or other famous figures. Many investors might prefer to do their own research before buying shares of a company, but it's still a good idea to pay attention to some of the moves more experienced names on Wall Street make. Take Ken Griffin, a successful money manager and the billionaire CEO of Citadel Advisors, the hedge fund he founded. During the first quarter, Griffin and his team made several moves that investors, including those seeking reliable dividend payers, should seriously consider copying. The hedge fund added shares of Medtronic (NYSE: MDT) and AbbVie (NYSE: ABBV). Here's why these two are top options for dividend seekers. Medtronic checks several of the boxes that dividend investors look to find. Let's consider three of them. First, the company develops and markets medical devices. As a leader in a defensive industry, Medtronic tends to perform better than most even in challenging conditions. The business is highly unlikely to go under, which means there is less risk of payout cuts. Medtronic's shares have performed slightly better than the S&P 500 this year -- despite significant volatility and fears of a recession -- while it continues to generate steady revenue and profits. That's precisely what income seekers want. Second, Medtronic has several important growth avenues. The company is inching closer to approval in the U.S. for its Hugo device, a robotic-assisted surgery (RAS) system, in urologic procedures. That will mark the device's grand commercial entrance into the U.S. market. Medtronic should seek label expansions for it in the future. The RAS industry appears to be significantly underpenetrated. As Medtronic pointed out two years ago, less than 5% of procedures that could be performed robotically currently are. The company's Hugo system will unlock massive long-term growth opportunities and help it continue delivering consistent financial results just as it has been doing. Third, Medtronic has an impeccable dividend track record, having grown its payouts for 48 consecutive years. Its 3.4% forward yield is above the S&P 500's average of 1.3%. Medtronic currently faces some challenges, including the threat of tariffs. It expects a net tariff hit of between $200 million and $350 million during its fiscal year 2026 (which just started). However, Medtronic is looking for ways to mitigate the impact of tariffs. For its fiscal 2026, it projected revenue growth of 5% year over year and adjusted earnings-per-share (EPS) growth of 1% at the midpoint, including the impact of tariffs. These trade developments will harm the company in the short term, but Medtronic should find ways to minimize the negative impact in the long term if these tariffs remain in place for an extended period, which is by no means certain. In my view, even with that threat, Medtronic remains a top stock to buy and hold for the long term, especially for dividend seekers. AbbVie's shares fell off a cliff in November after an otherwise promising pipeline program flopped in a phase 2 study. The drugmaker is no stranger to clinical setbacks. No pharmaceutical giant is. However, AbbVie's underlying business still looks incredibly solid. The company's revenue and earnings are growing at a good clip largely thanks to its two immunology superstars, Skyrizi and Rinvoq. Management expects these medicines to hit $31 billion in combined sales by 2027 (versus $17.7 billion last year). However, AbbVie's greatest strength isn't its current lineup of immunology medicines. It's the company's ability to overcome clinical setbacks and major patent cliffs by successfully developing newer and better medicines. Skyrizi and Rinvoq helped AbbVie move beyond Humira, its former top-selling medicine, which lost U.S. patent exclusivity in January 2023. Skyrizi and Rinvoq overlap with many of Humira's indications, sometimes with greater efficacy. AbbVie's deep pipeline should enable it to develop successors to its current crop of drugs even if it has to endure setbacks along the way. AbbVie's business is impressive and so is its dividend history. The company has increased its payouts for 53 consecutive years -- making it a Dividend King -- and currently offers a forward yield of 3.6%. AbbVie is an outstanding dividend stock despite the issues it has encountered in the past two years. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks was originally published by The Motley Fool
